Ambeed.cn

首页 / / / / JNJ-7706621

JNJ-7706621 99%+

货号:A262123 同义名: Aurora A Inhibitor I;Aurora Kinase/CDK Inhibitor Ambeed 开学季,买赠积分,赢豪礼

JNJ-7706621 is a pan-CDK inhibitor that inhibits CDK1/2 with IC50 of 9/4 nM, also potently inhibits Aurora A/B.

JNJ-7706621 化学结构 CAS号:443797-96-4
JNJ-7706621 化学结构
CAS号:443797-96-4
JNJ-7706621 3D分子结构
CAS号:443797-96-4
JNJ-7706621 化学结构 CAS号:443797-96-4
JNJ-7706621 3D分子结构 CAS号:443797-96-4
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

JNJ-7706621 纯度/质量文件 产品仅供科研

货号:A262123 标准纯度: 99%+
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell,2024. Ambeed. [ A125712 ]
Cancer Discov., 2024. Ambeed. [ A285925 ]
JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]
JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >
产品名称 Aurora A Aurora B Aurora C 其他靶点 纯度
BI-847325 ++

Aurora A (Human), IC50: 25 nM

++++

Aurora B (Xenopus laevis), IC50: 3 nM

++

Aurora C (Human), IC50: 15 nM

99%+
CCT 137690 ++

Aurora A, IC50: 15 nM

++

Aurora B, IC50: 25 nM

++

Aurora C, IC50: 19 nM

99%+
MK-5108 ++++

Aurora A, IC50: 0.064 nM

99%+
KW-2449 +

Aurora A, IC50: 48 nM

FLT3 99%+
Tozasertib ++++

Aurora A, Ki app: 0.6 nM

++

Aurora B, Ki app: 18 nM

+++

Aurora C, Ki app: 4.6 nM

FLT3,Bcr-Abl 99%+
AT9283 ++++

Aurora A, IC50: ~3.0 nM

++++

Aurora B, IC50: ~3.0 nM

99%+
MLN8054 +++

Aurora A, IC50: 4 nM

+

Aurora B, IC50: 172 nM

99%+
ZM-447439 +

Aurora A, IC50: 110 nM

+

Aurora B, IC50: 130 nM

Src 99%+
TCS7010 ++++

Aurora A, IC50: 3.4 nM

99%+
TAK-901 ++

Aurora A-TPX2, IC50: 21 nM

++

Aurora B-INCENP, IC50: 15 nM

99%+
Danusertib +++

Aurora A, IC50: 13 nM

+

Aurora B, IC50: 79 nM

+

Aurora C, IC50: 61 nM

RET 99%+
MK-8745 ++++

Aurora A, IC50: 0.6 nM

99+%
PHA-680632 ++

Aurora A, IC50: 27 nM

+

Aurora B, IC50: 135 nM

+

Aurora C, IC50: 120 nM

FLT3 99%+
AMG 900 +++

Aurora A, IC50: 5 nM

+++

Aurora B, IC50: 4 nM

++++

Aurora C, IC50: 1 nM

99%+
Alisertib ++++

Aurora A, IC50: 1.2 nM

99%+
ENMD-2076 +++

Aurora A, IC50: 14 nM

+

Aurora B, IC50: 350 nM

RET,FLT3 98%
JNJ-7706621 +++

Aurora A, IC50: 11 nM

++

Aurora B, IC50: 15 nM

99%+
CYC-116 +++

Aurora A, Ki: 8 nM

+++

Aurora B, Ki: 9 nM

FLT3 99%+
Reversine +++

Aurora A, IC50: 12 nM

+++

Aurora B, IC50: 13 nM

++

Aurora C, IC50: 20 nM

98%
CCT129202 ++

Aurora A, IC50: 42 nM

+

Aurora B, IC50: 198 nM

+

Aurora C, IC50: 227 nM

98%
SNS-314 mesylate +++

Aurora A, IC50: 9 nM

++

Aurora B, IC50: 31 nM

++++

Aurora C, IC50: 3 nM

99%+
Barasertib-HQPA ++++

Aurora B, IC50: 0.37 nM

99%+
Hesperadin +

Aurora B (human), IC50: 250 nM

98%
GSK-1070916 ++++

Aurora B-INCENP, IC50: 3.5 nM

+++

Aurora C-INCENP, IC50: 6.5 nM

SIK,Tie-2 99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Cdc CDK1 CDK19 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CLK 其他靶点 纯度
XL413 hydrochloride ++++

Cdc7, IC50: 3.4 nM

99%+
SU9516 +++

CDK1, IC50: 40 nM

+++

CDK2, IC50: 22 nM

++

CDK4, IC50: 200 nM

99%+
RO-3306 +++

CDK1, Ki: 20 nM

SGK,ERK 98%
R547 ++++

CDK1/CyclinB, Ki: 2 nM

++++

CDK2/CyclinE, Ki: 3 nM

++++

CDK4/CyclinD1, Ki: 1 nM

99%+
BMS-265246 ++++

CDK1/CyclinB, IC50: 6 nM

++++

CDK2/CyclinE, IC50: 9 nM

+

CDK4/CyclinD, IC50: 230 nM

99%+
NU6027 +

CDK1, Ki: 2.5 μM

+

CDK2, Ki: 1.3 μM

DNA-PK 98%
Purvalanol A ++++

Cdc2/CyclinB, IC50: 4 nM

+++

CDK2/CyclinE, IC50: 35 nM

CDK2/CyclinA, IC50: 70 nM

+

CDK4/CyclinD1, IC50: 850 nM

99%+
SCH900776 ++

CDK2, IC50: 0.16 μM

99%+
AUZ 454 ++++

CDK2(A144C), Kd: 9.7 nM

CDK2(C118L), Kd: 18.6 nM

99%+
A-674563 HCl ++

CDK2, Ki: 46 nM

PKA 98%
JNJ-7706621 ++++

CDK1/CyclinB, IC50: 9 nM

++++

CDK2/CyclinE, IC50: 3 nM

CDK2/CyclinA, IC50: 4 nM

++

CDK3/CyclinE, IC50: 58 nM

+

CDK4/CyclinD1, IC50: 253 nM

++

CDK6/CyclinD1, IC50: 175 nM

99%+
AT7519 ++

CDK1/CyclinB, IC50: 210 nM

++

CDK2/CyclinA, IC50: 47 nM

+

CDK3/CyclinE, IC50: 360 nM

++

CDK4/CyclinD1, IC50: 100 nM

+++

CDK5/p35, IC50: 13 nM

++

CDK6/CyclinD3, IC50: 170 nM

++++

CDK9/CyclinT, IC50: <10 nM

98+%
PHA-793887 ++

CDK1/CyclinB, IC50: 60 nM

++++

CDK2/CyclinE, IC50: 8 nM

CDK2/CyclinA, IC50: 8 nM

++

CDK4/CyclinD1, IC50: 62 nM

++++

CDK5/p25, IC50: 5 nM

++++

CDK7/CyclinH, IC50: 10 nM

++

CDK9/CyclinT1, IC50: 138 nM

99%+
Milciclib +

CDK1/CyclinB, IC50: 398 nM

++

CDK2/CyclinE, IC50: 363 nM

CDK2/CyclinA, IC50: 45 nM

++

CDK4/CyclinD1, IC50: 160 nM

+

CDK5/p35, IC50: 265 nM

++

CDK7/CyclinH, IC50: 150 nM

99%+
Kenpaullone +

CDK1/CyclinB, IC50: 0.4μM

+

CDK2/CyclinE, IC50: 7.5μM

CDK2/CyclinA, IC50: 0.68μM

+

CDK5/p35, IC50: 0.85μM

98%
SNS-032 +++

CDK2/CyclinE, IC50: 48 nM

CDK2/CyclinA, IC50: 38 nM

+

CDK5/p35, IC50: 340 nM

++

CDK7/CyclinH, IC50: 62 nM

++++

CDK9/CyclinT, IC50: 4 nM

99%+
Dinaciclib ++++

CDK1, IC50: 3 nM

++++

CDK2, IC50: 1 nM

++++

CDK5, IC50: 1 nM

++++

CDK9, IC50: 4 nM

99%+
PHA-767491 hydrochloride ++++

Cdc7, IC50: 10 nM

+

CDK1, IC50: 250 nM

+

CDK2, IC50: 240 nM

+

CDK5, IC50: 460 nM

+++

CDK9, IC50: 34 nM

MK2 98%
(R)-Roscovitine +

Cdc2/CyclinB, IC50: 0.65 μM

+

CDK2/CyclinE, IC50: 0.7 μM

CDK2/CyclinA, IC50: 0.7 μM

++

CDK5/p35, IC50: 0.16 μM

99%+
Narazaciclib ++++

CDK4/CyclinD1, IC50: 3.87 nM

++++

CDK6/CyclinD1, IC50: 9.82 nM

RET 99%+
Palbociclib ++++

CDK4/CyclinD3, IC50: 9 nM

CDK4/CyclinD1, IC50: 11 nM

+++

CDK6/CyclinD2, IC50: 15 nM

99%
Abemaciclib ++++

CDK4, IC50: 2 nM

++++

CDK6, IC50: 10 nM

99%
Ribociclib ++++

CDK4, IC50: 10 nM

+++

CDK6, IC50: 39 nM

98%
Palbociclib isethionate ++++

CDK4/CyclinD3, IC50: 9 nM

CDK4/CyclinD1, IC50: 11 nM

+++

CDK6/CyclinD2, IC50: 15 nM

99%+
BS-181 HCl +++

CDK7, IC50: 21 nM

99%+
(E/Z)-THZ1 dihydrochloride ++++

CDK7, IC50: 3.2 nM

99%+
LDC4297 ++++

CDK7, IC50: 0.13 nM

99%+
Senexin A +

CDK19, Kd: 0.31 μM

+

CDK8, Kd: 0.83 μM

98+%
MSC2530818 ++++

CDK8, IC50: 2.6 nM

99%+
Wogonin 99%+
Riviciclib HCl ++

CDK1/CyclinB, IC50: 79 nM

+

CDK2/CyclinE, IC50: 2.54 μM

CDK2/CyclinA, IC50: 224 nM

++

CDK4/CyclinD1, IC50: 63 nM

+

CDK6/CyclinD3, IC50: 396 nM

+

CDK7/CyclinH, IC50: 2.87 μM

+++

CDK9/CyclinT1, IC50: 20 nM

99+%
LDC000067 +

CDK2, IC50: 2.441 μM

++

CDK9, IC50: 44 nM

98%
Flavopiridol +++

CDK1, IC50: 40 nM

+++

CDK2, IC50: 40 nM

+++

CDK4, IC50: 40 nM

+++

CDK6, IC50: 40 nM

+

CDK7, IC50: 300 nM

+++

CDK9, IC50: 20 nM

99%+
LY2857785 +

CDK7, IC50: 0.246 μM

+++

CDK8, IC50: 0.016 μM

+++

CDK9, IC50: 0.011 μM

99%+
AZD-5438 +++

CDK1, IC50: 16 nM

++++

CDK2, IC50: 6 nM

+++

CDK9, IC50: 20 nM

99%+
ML167 ++

Dyrk1B , IC50: 1648 nM

CLK4, IC50: 136 nM

99%+
(E/Z)-TG003 +++

mCLK4, IC50: 15 nM

mCLK1, IC50: 200 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

JNJ-7706621 生物活性

靶点
  • Aurora A

    Aurora A, IC50:11 nM

  • Aurora B

    Aurora B, IC50:15 nM

  • CDK4

    CDK4/CyclinD1, IC50:253 nM

  • CDK2

    CDK2/CyclinE, IC50:3 nM

    CDK2/CyclinA, IC50:4 nM

描述 Cyclin-dependent kinases (CDKs) are a family of serine/threonine protein kinases that participate in cell cycle regulation. The functionally distinct kinase complexes are formed by the combination of catalytic kinase subunits (such as CDK1, CDK2, CDK4, or CDK6) with regulatory cyclin subunits (such as cyclin A, B, D1, D2, D3, or E). Coordinated activation of these complexes at specific times drives cells through the cell cycle and ensures the fidelity of cell division. The Aurora kinases also have a critical role in controlling chromosome movement and organization, thus regulating cell cycle. Aurora-A contributes to formation of the mitotic spindle apparatus that guarantees accurate segregation of chromosomes into daughter cells; Aurora-B is required for cytokinesis and proper chromosome architecture during mitosis. JNJ-7706621 is a dual CDK and aurora inhibitor. Based on results from in vitro kinase assays utilizing human recombinant enzymes, JNJ-7706621 inhibited CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B with IC50s of 9 nM, 4 nM, 3 nM, 11 nM and 15 nM, respectively. JNJ-7706621 showed potent growth inhibition in vitro on human cancer cell lines of Hela, HCT-116, SKOV-3, PC3, A375, MDA-MB-231, DU145 with IC50 values ranging from 112 to 514 nM. Cell cycle analysis on Hela cells synchronized in G1 showed that cells treated with 3 μM JNJ-7706621 did not enter the S phase until 16 hours after G1 synchronization, indicating that JNJ-7706621 delayed exit from G1 and arrested cells in G2-M. In a human tumor xenograft model established by implantation of A375 tumor fragments in female nu/nu mice, JNJ-7706621 given i.p. when the tumors reached approximately 62 to 126 mg at the dose of 125 mg/kg with the 7 on/7 off schedule or the 100 mg/kg daily schedule both produced identical tumor growth inhibition values of 93%[3].

JNJ-7706621 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
HCT116 cells Function assay In vitro inhibitory concentration against cell proliferation in human HCT116 (colon carcinoma) tumor cells, IC50=0.25 μM 15974571
human A375 cells Proliferation assay Antiproliferative activity against human A375 cells, IC50=0.447 μM 16682186
human HeLa cells Function assay In vitro inhibitory concentration against cell proliferation in human HeLa (cervical adenocarcinoma) tumor cells, IC50=0.28 μM 15974571
MDA-MB-231 cells Function assay In vitro inhibitory concentration against cell proliferation in various human MDA-MB-231 (breast carcinoma) tumor cells, IC50=0.59 μM 15974571

JNJ-7706621 动物研究

Dose Mice: 30 mg/kg[3] (i.p.), 125 mg/kg[2] (i.p.); 3.25 mg/kg[4] (i.v.)
Administration i.p., i.v.

JNJ-7706621 参考文献

[1]Seamon JA, Rugg CA, et al. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol Cancer Ther. 2006 Oct;5(10):2459-67.

[2]Emanuel S, Rugg CA, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005 Oct 1;65(19):9038-46.

[3]Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L, Middleton SA. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005 Oct 1;65(19):9038-46.

JNJ-7706621 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.54mL

0.51mL

0.25mL

12.68mL

2.54mL

1.27mL

25.36mL

5.07mL

2.54mL

JNJ-7706621 技术信息

CAS号443797-96-4
分子式C15H12F2N6O3S
分子量 394.356
别名 Aurora A Inhibitor I;Aurora Kinase/CDK Inhibitor
运输蓝冰
存储条件

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 120 mg/mL(304.29 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+30% PEG300+water 10 mg/mL clear

PO 0.5% CMC-Na 52 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。